|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
|
US4911920A
(en)
|
1986-07-30 |
1990-03-27 |
Alcon Laboratories, Inc. |
Sustained release, comfort formulation for glaucoma therapy
|
|
FR2588189B1
(fr)
|
1985-10-03 |
1988-12-02 |
Merck Sharp & Dohme |
Composition pharmaceutique de type a transition de phase liquide-gel
|
|
ATE141502T1
(de)
|
1991-01-15 |
1996-09-15 |
Alcon Lab Inc |
Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
|
|
US5212162A
(en)
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
|
ATE177101T1
(de)
|
1992-12-17 |
1999-03-15 |
Pfizer |
Pyrrolopyrimidine als crf antagonisten
|
|
JPH0971528A
(ja)
*
|
1995-07-05 |
1997-03-18 |
Hayashibara Biochem Lab Inc |
抗腫瘍剤
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
JP3356291B2
(ja)
|
1996-02-07 |
2002-12-16 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Ｃｒｆレセプター拮抗薬としてのピラゾロピリミジン類
|
|
BR9707495A
(pt)
|
1996-02-13 |
1999-07-27 |
Zeneca Ltd |
Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
|
|
US6291455B1
(en)
|
1996-03-05 |
2001-09-18 |
Zeneca Limited |
4-anilinoquinazoline derivatives
|
|
HU228962B1
(en)
|
1996-07-24 |
2013-07-29 |
Bristol Myers Squibb Pharma Co |
Azolo triazines, pharmaceutical compositions containing them and use of the compounds
|
|
IL127566A0
(en)
|
1996-08-28 |
1999-10-28 |
Pfizer |
Substituted 6,5-hetero- bicyclic derivatives
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
GB9714249D0
(en)
|
1997-07-08 |
1997-09-10 |
Angiogene Pharm Ltd |
Vascular damaging agents
|
|
IL137019A
(en)
|
1998-01-28 |
2010-11-30 |
Du Pont Pharm Co |
2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
|
|
GB9900334D0
(en)
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
|
GB9900752D0
(en)
|
1999-01-15 |
1999-03-03 |
Angiogene Pharm Ltd |
Benzimidazole vascular damaging agents
|
|
EP1040831A3
(en)
|
1999-04-02 |
2003-05-02 |
Pfizer Products Inc. |
Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
|
|
WO2000059908A2
(en)
|
1999-04-06 |
2000-10-12 |
Du Pont Pharmaceuticals Company |
Pyrazolopyrimidines as crf antagonists
|
|
FR2796380B3
(fr)
|
1999-07-15 |
2001-08-17 |
Sanofi Synthelabo |
Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
|
|
EP1218381B1
(en)
|
1999-09-30 |
2006-12-06 |
Neurogen Corporation |
AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES
|
|
JP2003516353A
(ja)
|
1999-12-08 |
2003-05-13 |
ファルマシア コーポレイション |
ヴァルデコキシブ組成物
|
|
NZ522074A
(en)
|
2000-05-31 |
2004-06-25 |
Astrazeneca Ab |
Indole derivatives with vascular damaging activity
|
|
IL153484A0
(en)
|
2000-07-07 |
2003-07-06 |
Angiogene Pharm Ltd |
Colchinol derivatives as angiogenesis inhibitors
|
|
CN1255392C
(zh)
|
2000-07-07 |
2006-05-10 |
安吉奥金尼药品有限公司 |
作为血管生成抑制剂的秋水仙醇衍生物
|
|
BR0208357A
(pt)
|
2001-03-13 |
2004-06-29 |
Bristol Myers Squibb Pharma Co |
Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto
|
|
US20050085479A1
(en)
|
2003-08-27 |
2005-04-21 |
Pharmacia Corporation |
Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
|
|
CA2547639A1
(en)
|
2003-12-02 |
2005-06-16 |
B&B Beheer Nv |
Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
|
|
CA2550948A1
(en)
|
2003-12-22 |
2005-07-14 |
Sb Pharmco Puerto Rico Inc. |
Crf receptor antagonists and methods relating thereto
|
|
WO2005079807A1
(en)
|
2004-02-13 |
2005-09-01 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
|
|
WO2005079868A2
(en)
|
2004-02-13 |
2005-09-01 |
Sb Pharmco Puerto Rico Inc |
Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
|
|
WO2006124047A2
(en)
|
2004-08-13 |
2006-11-23 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
|
AU2006227300B2
(en)
|
2005-03-21 |
2012-02-02 |
Eli Lilly And Company |
Imidazopyridazine compounds
|
|
CA2644445A1
(en)
*
|
2006-03-29 |
2007-10-04 |
Velacor Therapeutics Pty Ltd |
Inorganic selenium for treatment of benign tumors
|
|
CN101516835A
(zh)
|
2006-07-19 |
2009-08-26 |
俄亥俄州立大学研究基金会 |
选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
|
|
AU2007297481B2
(en)
|
2006-09-20 |
2012-03-08 |
Eli Lilly And Company |
Thiophene pyrazolopyrimidine compounds
|
|
EP2094709B1
(en)
*
|
2006-09-20 |
2010-09-15 |
Eli Lilly And Company |
Thiazole pyrazolopyrimidines as crf1 receptor antagonists
|
|
US8952207B2
(en)
|
2007-09-11 |
2015-02-10 |
The University Of Houston System |
Copper-catalyzed C—H bond arylation
|
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
|
US20100203048A1
(en)
*
|
2008-04-30 |
2010-08-12 |
Stephen Evans-Freke |
Methods of using corticotropin-releasing factor for the use of the treatment of cancer
|
|
WO2010039678A1
(en)
|
2008-10-02 |
2010-04-08 |
Eli Lilly And Company |
Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
|
|
EP4718073A2
(en)
|
2008-12-24 |
2026-04-01 |
Quest Diagnostics Investments Incorporated |
Mass spectrometry assay for congenital adrenal hyperplasia
|
|
PL2519230T3
(pl)
|
2009-12-31 |
2019-05-31 |
Marius Pharmaceuticals Llc |
Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
|
|
US9750568B2
(en)
|
2012-03-08 |
2017-09-05 |
Medtronic Ardian Luxembourg S.A.R.L. |
Ovarian neuromodulation and associated systems and methods
|
|
HK1207304A1
(en)
|
2012-04-23 |
2016-01-29 |
Hmnc Value Gmbh |
Crhr1 antagonists for use in the treatment of patients having crh overactivity
|
|
WO2015112642A1
(en)
*
|
2014-01-21 |
2015-07-30 |
Neurocrine Biosciences, Inc. |
Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
|
|
AU2016242867B2
(en)
|
2015-03-31 |
2020-11-05 |
May Health Us Inc. |
Methods and systems for the manipulation of ovarian tissues
|
|
EA202090321A1
(ru)
*
|
2017-08-14 |
2020-09-24 |
Спрюс Биосайнсес, Инк. |
Антагонисты рецептора кортикотропин-рилизинг фактора
|
|
CN118845788A
(zh)
|
2017-08-14 |
2024-10-29 |
云杉生物科学公司 |
促肾上腺皮质激素释放因子受体拮抗剂
|
|
EP4438124A3
(en)
|
2018-04-27 |
2024-12-18 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
|
CA3121920A1
(en)
|
2018-12-07 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
|
|
US20200255436A1
(en)
|
2019-02-12 |
2020-08-13 |
Spruce Biosciences, Inc. |
Corticotropin releasing factor receptor antagonists
|
|
TW202116324A
(zh)
|
2019-07-19 |
2021-05-01 |
美商雲杉生物科技股份有限公司 |
治療先天性腎上腺增生之方法
|
|
BR112023002497A2
(pt)
|
2020-08-12 |
2023-05-02 |
Spruce Biosciences Inc |
Métodos e composições para tratamento da síndrome dos ovários policísticos
|
|
US11708372B2
(en)
|
2021-11-19 |
2023-07-25 |
Spruce Biosciences, Inc. |
Crystalline composition of tildacerfont and methods of use and preparation thereof
|
|
MX2024006064A
(es)
|
2021-11-19 |
2024-05-30 |
Spruce Biosciences Inc |
Composicion cristalina de tildacerfont y metodos de uso y preparacion de la misma.
|